Work

LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.5050

Authors: Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Tina M. Mayer, Sarah Torneten, James Babb, Mary-Ellen Taplin, Robert S. DiPaola, Tomasz M. Beer

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Oregon Health & Science University, Rutgers Cancer Institute, New York University, Dana-Farber Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2231422459

Cites:

Cited by: 1

Related to: 10